Important new data from EORTC trials to be presented at ESMO 2022
5 Sep 2022
EORTC will present significant new results, updates, and future EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer at the ESMO 2022 conference which will take place on September 9 in Paris. Once again, immunotherapy plays a leading role, as do patients’ quality of life studies. Eight abstracts were accepted, with four oral presentations, a proffered paper, and three poster displays.
EORTC data accepted at ESMO:
| Cancer type | Abstract Title | Abstract Number/Presentation Details |
|---|---|---|
| Lung cancer | LBA51 – Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial | Abstract #LBA51 Proffered Paper Session Sunday, 11 September at 14:45 |
| Testicular cancer | 512MO – Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database | Abstract #512MO Mini-Oral Session Sunday 11 September at 15:50 |
| Melanoma | LBA44 – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial | Abstract #LBA44 Mini-Oral Session Monday, 12 September at 09:10 |
| Lung cancer | 930MO – PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091 | Abstract #930MO Mini-Oral Session Monday, 12 September at 14:50 |
| Soft tissue and bone sarcoma | 1491MO – New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis | Abstract #1491MO Mini-Oral Session Monday, 12 September at 15:20 |
| Soft tissue sarcoma | 1526TiP – TOLERANCE: An EORTC STBSG-QLG-ETF 3-arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment | Abstract #1526TiP Poster display |
| Melanoma | 804P – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial | Abstract #804P Poster display |
| Head and neck cancer | 706TiP – Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma, and with T1, N0 hypopharyngeal carcinoma | Abstract #706TiP Poster display |
Related News
EORTC Quality of Life Group participating at the ISOQOL 2025 Conference
22 Oct 2025
New results and forthcoming trials presented at ESMO 2025 underline EORTC’s commitment to patient-centred research
21 Oct 2025
EORTC celebrates the 100th anniversary of p-value on World Statistics Day
20 Oct 2025
EORTC Announces Final Overall Survival Results from the PEACE-3 Trial
19 Oct 2025
Results from EORTC trial define new standard of care for aggressive brain tumours
18 Oct 2025
EORTC’s presence at ESMO 2025
17 Oct 2025
EORTC’s presence at EANO 2025
16 Oct 2025
EORTC celebrates Pink October: shaping the future of breast cancer care
15 Oct 2025
EORTC shines a light on advancements in radioligand therapy
8 Oct 2025
Treatment optimisation: making cancer treatment accessible and sustainable in Europe
24 Sep 2025
